The term critical limb ischemia refers to a condition characterized by chronic ischemic rest pain, ulcers, or gangrene in one or both legs attributable to objectively proven arterial occlusive disease.
Peripheral arterial disease affects 12% of the adult population and up to 20% of elderly persons. The most severe form of peripheral arterial disease is critical limb ischemia which occurs when arterial blood flow is restricted so severely that perfusion of capillary beds is inadequate to sustain tissue viability.
Diabetic ischemic foot may cause significant chronic pain, sepsis, tissue loss, eventual amputation, or even death. Conventional treatment involves bypass surgery and balloon angioplasty. Studies have shown that bone marrow mesenchymal stem cells therapy increased lower limb perfusion and promoted foot ulcer healing in diabetic patients with critical limb ischemia.
Revascularization is the restoration of blood flow to a body part or organ that has suffered ischemia, typically accomplished by surgical means. Non-revascularizable critical limb ischemia is the most severe stage of peripheral arterial disease, with no therapeutic option. Extensive preclinical studies have demonstrated that adipose-derived stroma cells transplantation strongly improves revascularization wound healing and tissue perfusion in ischemic limbs.
Local injection of stem cells or endothelial progenitors directly into the ischemic tissue remains an option for the management of arterial occlusion. Bone marrow-derived mesenchymal stem cells represent a promising autologous cell source for ischemic limb cell therapy. Hypoxic mesenchymal stem cells are immune-privileged and can serve as a ‘universal donor cell’ for treating cardiovascular diseases.
Stem Cells transplant institute, aims to provide our patients the highest standards of quality, top technologies and high-skilled professionals for you to get into this new treatment trend.